PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25304214-0 2015 Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal. Arsenic Trioxide 55-71 transforming growth factor beta 1 Homo sapiens 115-146 26517826-2 2015 Arsenic trioxide (ATO) upregulates expression of TGF-beta1, promoting collagen synthesis in osteoblasts, and ATO binds directly to PML to induce oligomerization, sumoylation, and ubiquitination. Arsenic Trioxide 0-16 transforming growth factor beta 1 Homo sapiens 49-58 26517826-2 2015 Arsenic trioxide (ATO) upregulates expression of TGF-beta1, promoting collagen synthesis in osteoblasts, and ATO binds directly to PML to induce oligomerization, sumoylation, and ubiquitination. Arsenic Trioxide 18-21 transforming growth factor beta 1 Homo sapiens 49-58 25304214-9 2015 Knockdown of either miR-491 or SMAD3 attenuated the As2O3-induced inhibition of endogenous transforming growth factor beta signal and the CSCs-like properties. Arsenic Trioxide 52-57 transforming growth factor beta 1 Homo sapiens 91-122 25283513-0 2014 Inhibition of transforming growth factor beta/SMAD signal by MiR-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer. Arsenic Trioxide 84-100 transforming growth factor beta 1 Homo sapiens 14-45 25283513-7 2014 Briefly, As2 O3 inhibited the activations/expressions of both TGFbeta-induced and endogenous SMAD2/3. Arsenic Trioxide 9-15 transforming growth factor beta 1 Homo sapiens 62-69 22853924-4 2012 ATO promoted collagen production and TGF-beta1 expression and secretion in cultured CFs. Arsenic Trioxide 0-3 transforming growth factor beta 1 Homo sapiens 37-46 25196641-0 2014 Inhibition of TGF-beta/SMAD3/NF-kappaB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells. Arsenic Trioxide 80-96 transforming growth factor beta 1 Homo sapiens 14-22 25196641-6 2014 In our present study, As2O3 attenuated the angiogenic ability by the microRNA-491 (miR-491)-mediated inhibition of TGF-beta/SMAD3/NF-kappaB signal pathway in MHCC97H and MHCC97L cells. Arsenic Trioxide 22-27 transforming growth factor beta 1 Homo sapiens 115-123 25128771-7 2014 Mechanically, western blot results demonstrated that low dose of ATO dramatically up-regulated TGF-beta1 protein and activated p-AKT proliferative signaling. Arsenic Trioxide 65-68 transforming growth factor beta 1 Homo sapiens 95-104 24762191-4 2014 METHODS: To identify the mechanism of Arsenic trioxide"s (ATO)"s anti-fibrotic effect in vitro, normal human lung fibroblasts (NHLFs) were treated with ATO for 24 hours and were then exposed to TGF-beta1 (1 ng/ml) before harvesting at multiple time points. Arsenic Trioxide 38-54 transforming growth factor beta 1 Homo sapiens 194-203 22853924-7 2012 CM and CF co-cultures showed that ATO significantly increased TGF-beta1 levels in the culture medium, whereas markedly reduced HERG and Kir2.1 protein levels were observed in CMs compared with ATO-treated CMs not co-cultured with CFs. Arsenic Trioxide 34-37 transforming growth factor beta 1 Homo sapiens 62-71 22853924-9 2012 CONCLUSION: ATO-induced TGF-beta1 secretion from CFs aggravates QT prolongation, suggesting that modulation of TGF-beta signalling may provide a novel strategy for the treatment of drug-induced LQTS. Arsenic Trioxide 12-15 transforming growth factor beta 1 Homo sapiens 24-33 22853924-9 2012 CONCLUSION: ATO-induced TGF-beta1 secretion from CFs aggravates QT prolongation, suggesting that modulation of TGF-beta signalling may provide a novel strategy for the treatment of drug-induced LQTS. Arsenic Trioxide 12-15 transforming growth factor beta 1 Homo sapiens 24-32 20699661-0 2010 SnoN/SkiL, a TGFbeta signaling mediator: a participant in autophagy induced by arsenic trioxide. Arsenic Trioxide 79-95 transforming growth factor beta 1 Homo sapiens 13-20 21649584-5 2011 In the present study, we demonstrated that ATO induced hepatocellular apoptosis via TGF-beta/Smad signalling and led to downstream induction of p21(WAF1/CIP1) (p21). Arsenic Trioxide 43-46 transforming growth factor beta 1 Homo sapiens 84-92 20723295-1 2010 This study was purposed to investigate the effects of TGF-beta1 and arsenic trioxide (As2O3) on cell apoptosis, cell cycle and changes of P27(Kip1), endogenous TGF-ss1, cyclin E and BCL-2 in HL-60 cells, and to explore the relationship between expression of P27(Kip1) and apoptosis induced by As2O3 and/or TGFss1. Arsenic Trioxide 293-298 transforming growth factor beta 1 Homo sapiens 54-63 20723295-4 2010 The TGF-beta1 (5 ng/ml) induced arrest of cells in G1 phase (p < 0.05) compared with As2O3 alone and As2O3 combined with TGF-ss1, while there was no difference with control. Arsenic Trioxide 88-93 transforming growth factor beta 1 Homo sapiens 4-13 20723295-4 2010 The TGF-beta1 (5 ng/ml) induced arrest of cells in G1 phase (p < 0.05) compared with As2O3 alone and As2O3 combined with TGF-ss1, while there was no difference with control. Arsenic Trioxide 104-109 transforming growth factor beta 1 Homo sapiens 4-13 19236751-1 2009 This study was aimed to investigate the effects of arsenic trioxide (As(2)O(3)) and/or transforming growth factor-beta1 (TGF-beta1)on cell apoptosis and the changes of P27(Kip1), cyclin E and endogenous TGF-beta1 mRNA levels in NB4 cells. Arsenic Trioxide 51-67 transforming growth factor beta 1 Homo sapiens 203-212 19236751-10 2009 After treating with As(2)O(3), P27(Kip1) and endogenous TGF-beta1 mRNA expressions of NB4 cells were up-regulated, and cyclin E mRNA expression was down-regulated. Arsenic Trioxide 20-29 transforming growth factor beta 1 Homo sapiens 56-65 29088724-8 2017 We show that As2O3 inhibits angiogenesis in the collagen-induced arthritis (CIA) synovium and consequently arthritis severity via significant suppression of TSP-1, TGF-beta1, CTGF and VEGF expression in the CIA synovium, plus in the RA-FLS and HDMECs co-culture as well as NH-FLS and HDMECs co-culture system along with the presence or absence of TNF-alpha treatment. Arsenic Trioxide 13-18 transforming growth factor beta 1 Homo sapiens 164-173 29088724-9 2017 Thus As2O3 has a significant anti-angiogenesis effect on the RA-FLS and CIA synovium via its inhibition of the RA angiogenic functional module of TSP-1, TGF-beta1, CTGF and VEGF and may have a potential for treating RA beyond cancer therapy. Arsenic Trioxide 5-10 transforming growth factor beta 1 Homo sapiens 153-162 32590737-7 2020 ATO significantly reduced the levels of TGF-beta1 at 5 mumol/L (P = .03), but showed no significant effects at 1 and 2.5 mumol/L (P > .05).ATO could mediate the immune regulation, which might contribute to improve hematopoietic recovery in SAA patients. Arsenic Trioxide 0-3 transforming growth factor beta 1 Homo sapiens 40-49 32590737-7 2020 ATO significantly reduced the levels of TGF-beta1 at 5 mumol/L (P = .03), but showed no significant effects at 1 and 2.5 mumol/L (P > .05).ATO could mediate the immune regulation, which might contribute to improve hematopoietic recovery in SAA patients. Arsenic Trioxide 139-142 transforming growth factor beta 1 Homo sapiens 40-49